Neuronetics, Inc.STIM

The NeuroStar® Advanced Therapy is marketed with remission rates of 62% and patient contact forms that promise a Neuronetics representative will call you back. Behind the polished landing pages, Neuronetics Inc. (STIM) just filed a March 2026 quarter showing $34.5 million in revenue against a $10.8 million net loss and $9.4 million of negative operating cash flow. The company’s $13.2 million cash position is shrinking at a pace that would make even the most optimistic adolescent patient pause; shareholders’ equity stands at just $13.3 million against $108.4 million in liabilities, a leverage ratio that reads like a balance-sheet cry for help.

Neuronetics sells a medical device-Transcranial Magnetic Stimulation-used in clinics and hospitals to treat major depressive disorder, including an adolescent indication. The company’s marketing rails trumpet safety, remission, and a simple contact form for prospective patients, but the filing evidence shows an operating company that is haemorrhaging cash and haemorrhaging equity. The $1.4 million R&D line item is thin even by micro-cap medtech standards, and the board’s latest share disclosure forms show insiders transacting while the diluted share count floats above 69.6 million shares.

According to the 10-Q filed for the quarter ended 31 March 2026, Neuronetics reported revenue of $34.5 million, net loss attributable to parent of $-10.8 million, operating loss of $-9.0 million, assets of $125.4 million, liabilities of $108.4 million, and stockholders’ equity of $13.3 million. Cash and cash equivalents at 31 March 2026 stood at $13.2 million, with net cash used in operating activities of $-9.4 million. Research and development expense was $1.4 million; inventories, net, were $4.7 million, up $432,000 from the prior quarter. Diluted EPS was $-0.16 on 69.6 million diluted shares. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1227636/000162828126000016/0001628281-26-000010-index.htm) On 20 May 2026, Neuronetics announced FDA clearance of an adolescent indication, but the company’s filings do not quantify revenue contribution from this label. The product’s patient-facing claims are supported by the NeuroStar® website pages, which state 83% response and 62% remission rates without specifying study size, comparator arms, or peer-reviewed sources in the cited snippets. (source: Is NeuroStar Safe & Proven?, https://www.neurostar.com/is-neurostar-safe-proven/)

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The SEC submissions JSON confirms Neuronetics’s filing cadence but does not provide market data; accordingly, this report confines itself to the filed financials and the named public developments. Investors seeking price history should consult their broker or a primary exchange feed.

The filing evidence shows a cash-burning, equity-depleting micro-cap with a single marketed device and thin R&D spend. The adolescent indication is real but unquantified; the marketing rails are polished but the balance sheet is thin. What is missing is any disclosure of device utilisation per quarter, installed base growth, ASP trends, or cash runway beyond the current quarter. Until Neuronetics publishes unit volumes or a cash runway table, the file must treat this as a thin-data situation rather than a growth story. A banker’s data pack would include ASP trends, installed base counts, payor mix, and a liquidity bridge beyond one quarter; none of these appear in the current filings.

Equally absent is any evidence of meaningful buybacks offsetting dilution: the 8-K and Form 4/3/8 filings show insider transactions but do not evidence systematic repurchases. The company’s liabilities are concentrated in current obligations, and the equity account is small relative to the liability pile, which elevates refinancing risk if operating cash outflows persist. The adolescent indication is a regulatory milestone, not a revenue milestone; the file cannot infer revenue contribution without disclosure.